[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

Launched by FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY · May 14, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new imaging technique that uses a special substance called \[68Ga\]Ga-Sa-DABI-4 to look at a protein known as STING, which is important for our immune system’s ability to fight cancer. By using a type of scan called positron emission tomography (PET), researchers hope to see how well this new imaging method can show STING expression in tumors. This could help doctors monitor how effective certain cancer treatments targeting STING might be.

To participate in this study, individuals must be at least 18 years old and have either suspected or newly diagnosed cancer. Unfortunately, those with non-cancerous diseases, pregnant individuals, or those who cannot give consent cannot join. Participants will undergo imaging procedures to see how well the new agent works and to ensure it is safe. This trial is currently recruiting patients, and anyone considering joining should discuss it with their healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. At least 18 years of age.
• • 2. Signed informed consent.
• • 3. Patients with suspected or newly diagnosed or previously malignant disease.
• Exclusion Criteria:
• • 1. Patients with non-malignant disease.
• • 2. Patients with pregnancy.
• • 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
• • 4. Known or expected hypersensitivity to \[68Ga\]Ga-Sa-DABI-4 or any of its components.
• • 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.